Business Context and Reporting Period
This filing is Brooks Automation, Inc.’s Form 10-K for the fiscal year ended September 30, 2014. The request identifies Azenta, Inc., but the filing’s registrant is Brooks Automation, Inc.; Azenta is the company’s later name. Brooks provides automation and cryogenic solutions for semiconductor manufacturing, adjacent technology markets, and life sciences through Brooks Product Solutions, Brooks Global Services, and Brooks Life Science Systems.
The filing presents continuing operations separately from the Granville-Phillips gas analysis and vacuum measurement business, which was sold in May 2014.
Financial Performance and Liquidity
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Revenue | $482.8 million | $422.4 million | +14% |
| Gross profit | $167.3 million | $132.3 million | +26% |
| Gross margin | 34.7% | 31.3% | +3.4 percentage points |
| Operating income (loss) | $(2.7) million | $(16.8) million | Improved by $14.1 million |
| Income (loss) from continuing operations | $1.5 million | $(7.1) million | Returned to profitability |
| Net income attributable to Brooks | $31.4 million | $(2.2) million | Includes discontinued-operation gain |
| Diluted EPS | $0.46 | $(0.03) | Includes $0.44 from discontinued operations |
| Operating cash flow | $53.8 million | $54.4 million | Broadly stable |
Fourth-quarter revenue was $122.5 million, gross profit was $41.4 million, operating loss was $0.6 million, income from continuing operations was $0.3 million, and net income attributable to Brooks was $0.2 million. Fourth-quarter 2013 revenue was $110.7 million and operating loss was $1.3 million.
Segment revenue was $325.6 million for Product Solutions, $94.1 million for Global Services, and $63.1 million for Life Science Systems. Life Science Systems grew 46%, supported by the Twinbank automated cold-storage platform and the Matrical acquisition. Segment operating income was $10.8 million, $12.5 million, and $(8.4) million, respectively.
- Cash and cash equivalents were $94.1 million; total cash, cash equivalents, and marketable securities were $245.5 million, up from $173.4 million.
- Working capital was $98.2 million, compared with $105.5 million in the prior year.
- Total assets were $778.0 million and total equity was $642.9 million.
- The filing discloses no conventional funded debt. Capital lease obligations totaled $8.3 million, including $0.9 million current and $7.4 million long term.
- Capital expenditures were $5.5 million. Dividends paid were $22.9 million, and the annual dividend declared increased to $0.34 per share from $0.32.
- Backlog was $126.9 million at September 30, 2014, including $113.6 million scheduled for delivery within 12 months.
Material Changes Versus the Prior Comparable Period
- Revenue increased 14%, reflecting stronger semiconductor capital-equipment demand and growth in life sciences.
- Gross margin expanded from 31.3% to 34.7% due to volume leverage, favorable product mix, and material and warranty-cost reductions.
- Operating loss narrowed substantially, although continuing operations remained only marginally profitable after restructuring, amortization, and other corporate costs.
- International revenue increased to 64% of total revenue from 58%, with Asia/Pacific revenue rising to $198.7 million from $154.4 million.
- The company acquired DMS for approximately $31.6 million, contributing $5.5 million of revenue but a $4.5 million net loss, including acquisition-related charges.
- The company sold Granville-Phillips for $87.0 million in cash and recorded a $56.8 million pretax gain and $26.9 million after-tax gain. This generated $30.0 million of discontinued-operation income and accounts for most of reported FY2014 net income.
- Restructuring charges were $6.3 million, including approximately 70 workforce reductions, product-line discontinuations, facility consolidation, and outsourcing of Polycold manufacturing.
- SG&A increased to $111.1 million from $96.5 million, partly due to higher incentive and stock-based compensation and a $2.6 million impairment of a note receivable.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that it expects continued growth in life sciences through internally developed products, including Twinbank, and acquisitions. It expects restructuring and manufacturing changes to improve future profitability. No specific revenue, earnings, or margin guidance was provided.
- Results remain exposed to the cyclical semiconductor capital-equipment market, competitive pricing, customer order timing, and technological change.
- The top ten customers represented approximately 37% of FY2014 revenue; Applied Materials represented 11%.
- International operations represented 64% of revenue and expose the company to foreign-exchange, political, trade, regulatory, and collection risks.
- Goodwill was $109.5 million and net intangible assets were $59.6 million. Management concluded that no goodwill impairment existed, but the conclusion depends on projected cash flows and discount rates.
- The company recorded a $2.6 million impairment on a subordinated note receivable; its estimated fair value was approximately $1.0 million and could change with the borrower’s performance and valuation assumptions.
- Letters of credit totaled $21.1 million, primarily supporting customer advances and performance obligations. Contractual obligations totaled $96.5 million, excluding uncertain tax settlements.
- Unrecognized tax benefits and related interest totaled approximately $5.8 million, while legal proceedings were not expected to have a material effect based on management’s assessment.
- Subsequent events included the approximately $16.0 million acquisition of FluidX on October 1, 2014 and a $0.10-per-share dividend declared on November 5, 2014.
Investor Verification Checklist
- Verify the registrant identity and name transition from Brooks Automation to Azenta.
- Separate sustainable continuing-operations earnings from the one-time Granville-Phillips disposal gain.
- Assess whether Life Science Systems can achieve profitability after reporting a segment operating loss of $8.4 million.
- Review semiconductor demand, backlog conversion, customer concentration, and exposure to Asia.
- Reconcile cash generation with marketable-security purchases, acquisitions, dividends, capital leases, and contractual commitments.
- Monitor goodwill, intangible assets, inventory reserves, and the impaired note receivable for further charges.
- Evaluate the effect of restructuring and outsourced manufacturing on future gross margins and operating expenses.